E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
Authors
Keywords
-
Journal
AIDS
Volume 26, Issue 13, Pages 1619-1624
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2012-06-13
DOI
10.1097/qad.0b013e3283560703
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine
- (2011) Lotke Tambuyzer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
- (2011) Calvin J Cohen et al. LANCET
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
- (2011) Jean-Michel Molina et al. LANCET
- Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies
- (2010) Lotke Tambuyzer et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes
- (2010) Eugene L. Asahchop et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics
- (2010) John S. Albin et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus–1 infection
- (2010) P.A. Gourraud et al. HUMAN IMMUNOLOGY
- Moderate Influence of Human APOBEC3F on HIV-1 Replication in Primary Lymphocytes
- (2010) L. C. F. Mulder et al. JOURNAL OF VIROLOGY
- APOBEC3G Contributes to HIV-1 Variation through Sublethal Mutagenesis
- (2010) H. A. Sadler et al. JOURNAL OF VIROLOGY
- Human APOBEC3G-Mediated Editing Can Promote HIV-1 Sequence Diversification and Accelerate Adaptation to Selective Pressure
- (2010) E.-Y. Kim et al. JOURNAL OF VIROLOGY
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
- (2009) H. Azijn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif
- (2009) A. Piantadosi et al. JOURNAL OF VIROLOGY
- Rates of evolutionary change in viruses: patterns and determinants
- (2008) Siobain Duffy et al. NATURE REVIEWS GENETICS
- Cytidine deamination induced HIV-1 drug resistance
- (2008) L. C. F. Mulder et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HIV-1 Vif, APOBEC, and Intrinsic Immunity
- (2008) Ritu Goila-Gaur et al. Retrovirology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started